Natalie Weiss

Natalie Weiss

Auto-generated profile, based on publicly available information

Natalie Weiss

Department of Otolaryngology ‐ Head and neck Surgery Mayo Clinic Jacksonville Florida USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2025 in The Laryngoscope
Verified
Journal Article
Closed access
EREric Delgado Rendon
Eric Delgado Rendon
NSNawfal Saleem
Nawfal Saleem
NWNatalie Weiss
Natalie Weiss
ARAmy Rutt
Amy Rutt

11 June 2025 in Journal of Voice
Verified
Journal Article
Closed access
CTChandler C. Thompson
Chandler C. Thompson
SMStacey M. Menton
Stacey M. Menton
ECEstephania Candelo
Estephania Candelo
NWNatalie Weiss
Natalie Weiss
ARAmy L. Rutt
Amy L. Rutt

7 January 2025 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
NWNatalie Weiss
Natalie Weiss
ECEstephania Candelo
Estephania Candelo
MBMargaret Bridges
Margaret Bridges
ARAmy Rutt
Amy Rutt
Introduction: Castleman disease (CD) refers to a heterogeneous group of lymphoproliferative disorders, which rarely involves the larynx. Our goal in this study is to elucidate the clinical presentation, diagnostic techniques, and treatment methods of laryngeal CD through a scoping review and the addition of a new case.Methods: Due to limited existing literature, we employed a mixed methodology for review. First, we searched Google Scholar using terms related to laryngeal CD. Subsequently, we screened abstracts using Covidence, drawing from databases such as PubMed, Science Direct, ProQuest, and EMBASE. We shortlisted studies for data extraction, focusing on clinical presentations, diagnostics, and treatment methodologies. Finally, we described our additional case.Results: Scoping review revealed five qualifying laryngeal CD articles. Presenting symptoms included dysphagia, hoarseness, and dyspnea. Diagnosis was always established through histopathologic analysis. Management included local excision or radiotherapy. In our additional case, a 71‐year‐old male with known CD presented with neck swelling, dysphagia, and dysphonia. Exam revealed lymphoid laryngeal and supraglottic hyperplasia and edema. Laryngeal symptoms improved with medical management of CD.Discussion: Given the rarity of laryngeal CD, its identification and management can be a challenge. Practitioners should be aware of characteristic points in a CD patient's history, physical exam, imaging, and biopsies. Local excision of obstructive lymphoid tissue and radiation are the best‐supported therapies. This study aims to build toward improvements in accurate diagnosis and appropriate treatment for laryngeal CD.

12 July 2025 in The Laryngoscope
Verified
Journal Article
Closed access
RDRockey Dahiya
Rockey Dahiya
NWNatalie Weiss
Natalie Weiss
RMRyan May
Ryan May
ACAna‐Maria Chindris
Ana‐Maria Chindris
JRJordan P. Reynolds
Jordan P. Reynolds
PPPhillip Pirgousis
Phillip Pirgousis

1 September 2025 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
RDRockey Dahiya
Rockey Dahiya
NWNatalie Weiss
Natalie Weiss
PWPrishae Wilson
Prishae Wilson
BVBastien A Valencia-Sanchez
Bastien A Valencia-Sanchez
PPPhillip Pirgousis
Phillip Pirgousis
Synchronous squamous cell carcinoma (SCC) and chronic lymphocytic leukemia (CLL) in the parotid gland is rare, with limited evidence on personalized treatment. We report a 75-year-old male with prior cutaneous SCC who presented with a hypermetabolic parotid mass and cervical lymphadenopathy; fine needle aspiration confirmed SCC. Surgery revealed poorly differentiated SCC and CLL in multiple lymph nodes. He underwent radiotherapy but developed regional SCC relapse without systemic CLL symptoms. Recurrence in the ear required extensive surgical resection and reconstruction. Genetic profiling showed high tumor mutational burden (>50 mutations/Mb) and mutations in ARID1B, CDKN2A, MSH2, PMS2, and TP53. He received six cycles of cemiplimab followed by cetuximab-based targeted therapy, based on rising circulating DNA levels. This case emphasizes the value of genetic profiling and tools like TMB, FISH, and immunohistochemistry for risk stratification and personalized treatment in managing advanced or complex parotid malignancies, including synchronous SCC and CLL, to optimize patient outcomes.

22 March 2026 in Eye & ENT Research
Verified
Journal Article
Open access
PDF file
NWNatalie Weiss
Natalie Weiss
KWKendra Walker
Kendra Walker
KGKaterina Green
Katerina Green
HDHannah Daniel
Hannah Daniel
ARAmy Rutt
Amy Rutt
Click on the article title to read more.